Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 28, 2013 21:00 ET | Source: Gentium S.p.A.

Gentium Announces Resignation of Board Member

VILLA GUARDIA (COMO), Italy, March 28, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that Dr. Glenn Cooper has resigned from the Company's Board of Directors,...
March 28, 2013 07:23 ET | Source: Gentium S.p.A.

Gentium Reports Fourth Quarter and Year End 2012 Financial Results

Total product sales of EUR 27.63 million (US$ 36.43 million) exceeding Company's product sales guidance of EUR 22-25 million (US$ 29-33 million) Defibrotide uptake increased by 35% with sales...
March 26, 2013 08:35 ET | Source: Gentium S.p.A.

Gentium Announces Initiation of Phase 1 study in Japan

VILLA GUARDIA (COMO), Italy, March 26, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today has announced that the medical team from the National University Corporation...
March 22, 2013 08:30 ET | Source: Gentium S.p.A.

Gentium Receives Negative Opinion From the CHMP on Defibrotide for the Treatment and Prevention of VOD

VILLA GUARDIA, Italy, March 22, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it has been informed by the European Medicines Agency's ("EMA") Committee for...
March 21, 2013 07:00 ET | Source: Gentium S.p.A.

Gentium to Report Fourth Quarter and Full Year 2012 Financial Results

VILLA GUARDIA (COMO), Italy, March 21, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) announced today that it will report its fourth quarter and full year 2012 financial results on Thursday,...
February 21, 2013 07:00 ET | Source: Gentium S.p.A.

Gentium Provides Update on the Review of Defibrotide Marketing Authorization

VILLA GUARDIA, Italy, Feb. 21, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that, the Company had presented an oral explanation at the European Medicines...
January 17, 2013 07:00 ET | Source: Gentium S.p.A.

Gentium Provides an Update on Defibrotide MAA to EMA

VILLA GUARDIA, Italy, Jan. 17, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it has been informed that the Company's Marketing Authorization Application...
December 18, 2012 07:00 ET | Source: Gentium S.p.A.

Gentium Submit 2nd LoOIs Response to the EMA's CHMP for Defibrotide MAA

VILLA GUARDIA, Italy, Dec. 18, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that it has submitted responses to the second List of Outstanding Issues ("LoOIs")...
December 13, 2012 07:00 ET | Source: Gentium S.p.A.

Results From Gentium's Treatment IND for Defibrotide Presented at the American Society of Hematology Annual Meeting

VILLA GUARDIA (COMO), Italy, Dec. 13, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that additional data from ongoing trials of Defibrotide were presented this...
December 07, 2012 07:00 ET | Source: Gentium S.p.A.

Data From Non HSCT VOD Patients Treated With Defibrotide and a Treatment IND Update to be Presented at the American Society of Hematology Annual Meeting

VILLA GUARDIA (COMO), Italy, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that an oral presentation and poster abstracts on Defibrotide will be...